


OTI Disclaimer:	The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
OTI Annotation:	This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
Components:	The ORF clone is ion-exchange column purified and shipped in a 2D barcoded Matrix tube containing 10ug of transfection-ready, dried plasmid DNA (reconstitute with 100 ul of water).
Reconstitution Method:	<ol style="list-style-type: none">1. Centrifuge at 5,000xg for 5min.2. Carefully open the tube and add 100ul of sterile water to dissolve the DNA.3. Close the tube and incubate for 10 minutes at room temperature.4. Briefly vortex the tube and then do a quick spin (less than 5000xg) to concentrate the liquid at the bottom.5. Store the suspended plasmid at -20°C. The DNA is stable for at least one year from date of shipping when stored at -20°C.
RefSeq:	NM_001102411.1 , NP_001095881.1
RefSeq Size:	2299 bp
RefSeq ORF:	1986 bp
Locus ID:	16644
UniProt ID:	O08677
Cytogenetics:	16 B1
Gene Summary:	(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting (By similarity).[UniProtKB/Swiss-Prot Function]

Product images:



Circular map for MR217206L3